Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).

Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M, Nathan P, Odunsi K, Okada H, Paulos CM, Pignata S, Schalper KA, Spranger S, Tortora G, Zarour H, Butterfield LH, Puzanov I.

J Immunother Cancer. 2019 Nov 29;7(1):332. doi: 10.1186/s40425-019-0798-3. Review.

2.

Genomics meets immunity in pancreatic cancer: Current research and future directions for pancreatic adenocarcinoma immunotherapy.

Bowers JS, Bailey SR, Rubinstein MP, Paulos CM, Camp ER.

Oncol Rev. 2019 Aug 1;13(2):430. doi: 10.4081/oncol.2019.430. eCollection 2019 Jul 22.

3.

Pro-Survival Lipid Sphingosine-1-Phosphate Metabolically Programs T Cells to Limit Anti-tumor Activity.

Chakraborty P, Vaena SG, Thyagarajan K, Chatterjee S, Al-Khami A, Selvam SP, Nguyen H, Kang I, Wyatt MW, Baliga U, Hedley Z, Ngang RN, Guo B, Beeson GC, Husain S, Paulos CM, Beeson CC, Zilliox MJ, Hill EG, Mehrotra M, Yu XZ, Ogretmen B, Mehrotra S.

Cell Rep. 2019 Aug 13;28(7):1879-1893.e7. doi: 10.1016/j.celrep.2019.07.044.

4.

Immune Evasion by Head and Neck Cancer: Foundations for Combination Therapy.

Horton JD, Knochelmann HM, Day TA, Paulos CM, Neskey DM.

Trends Cancer. 2019 Apr;5(4):208-232. doi: 10.1016/j.trecan.2019.02.007. Epub 2019 Mar 20. Review.

PMID:
30961829
5.

Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines.

Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rangel Rivera GO, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP, Paulos CM.

Front Immunol. 2019 Feb 20;10:263. doi: 10.3389/fimmu.2019.00263. eCollection 2019. Review.

6.

CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.

Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM.

Front Immunol. 2018 Jul 27;9:1740. doi: 10.3389/fimmu.2018.01740. eCollection 2018. Review.

7.

Molecular properties of gp100-reactive T-cell receptors drive the cytokine profile and antitumor efficacy of transgenic host T cells.

Eby JM, Smith AR, Riley TP, Cosgrove C, Ankney CM, Henning SW, Paulos CM, Garrett-Mayer E, Luiten RM, Nishimura MI, Baker BM, Le Poole IC.

Pigment Cell Melanoma Res. 2019 Jan;32(1):68-78. doi: 10.1111/pcmr.12724. Epub 2018 Aug 13.

PMID:
30009548
8.

Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy).

Ascierto PA, Brugarolas J, Buonaguro L, Butterfield LH, Carbone D, Daniele B, Ferris R, Fox BA, Galon J, Gridelli C, Kaufman HL, Klebanoff CA, Melero I, Nathan P, Paulos CM, Ruella M, Sullivan R, Zarour H, Puzanov I.

J Immunother Cancer. 2018 Jul 11;6(1):69. doi: 10.1186/s40425-018-0377-z. Review.

9.

In Vitro Priming of Adoptively Transferred T Cells with a RORγ Agonist Confers Durable Memory and Stemness In Vivo.

Hu X, Majchrzak K, Liu X, Wyatt MM, Spooner CJ, Moisan J, Zou W, Carter LL, Paulos CM.

Cancer Res. 2018 Jul 15;78(14):3888-3898. doi: 10.1158/0008-5472.CAN-17-3973. Epub 2018 May 16.

10.

Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8+ T Cells.

Johnson CB, May BR, Riesenberg BP, Suriano S, Mehrotra S, Garrett-Mayer E, Salem ML, Jeng EK, Wong HC, Paulos CM, Wrangle JM, Cole DJ, Rubinstein MP.

Cancer Res. 2018 Jun 1;78(11):3067-3074. doi: 10.1158/0008-5472.CAN-17-2153. Epub 2018 Apr 10.

11.

When worlds collide: Th17 and Treg cells in cancer and autoimmunity.

Knochelmann HM, Dwyer CJ, Bailey SR, Amaya SM, Elston DM, Mazza-McCrann JM, Paulos CM.

Cell Mol Immunol. 2018 May;15(5):458-469. doi: 10.1038/s41423-018-0004-4. Epub 2018 Mar 21. Review.

12.

IL-2 and Beyond in Cancer Immunotherapy.

Wrangle JM, Patterson A, Johnson CB, Neitzke DJ, Mehrotra S, Denlinger CE, Paulos CM, Li Z, Cole DJ, Rubinstein MP.

J Interferon Cytokine Res. 2018 Feb;38(2):45-68. doi: 10.1089/jir.2017.0101. Review.

13.

N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Scheffel MJ, Scurti G, Wyatt MM, Garrett-Mayer E, Paulos CM, Nishimura MI, Voelkel-Johnson C.

Cancer Immunol Immunother. 2018 Apr;67(4):691-702. doi: 10.1007/s00262-018-2120-5. Epub 2018 Feb 2.

14.

The clinical implications of immunogenomics in colorectal cancer: A path for precision medicine.

Riley JM, Cross AW, Paulos CM, Rubinstein MP, Wrangle J, Camp ER.

Cancer. 2018 Apr 15;124(8):1650-1659. doi: 10.1002/cncr.31214. Epub 2018 Jan 9. Review.

15.

Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence.

Bailey SR, Nelson MH, Majchrzak K, Bowers JS, Wyatt MM, Smith AS, Neal LR, Shirai K, Carpenito C, June CH, Zilliox MJ, Paulos CM.

Nat Commun. 2017 Dec 6;8(1):1961. doi: 10.1038/s41467-017-01867-9.

16.

Adoptive Transfer of Ceramide Synthase 6 Deficient Splenocytes Reduces the Development of Colitis.

Scheffel MJ, Helke K, Lu P, Bowers JS, Ogretmen B, Garrett-Mayer E, Paulos CM, Voelkel-Johnson C.

Sci Rep. 2017 Nov 14;7(1):15552. doi: 10.1038/s41598-017-15791-x.

17.

CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response.

Chatterjee S, Daenthanasanmak A, Chakraborty P, Wyatt MW, Dhar P, Selvam SP, Fu J, Zhang J, Nguyen H, Kang I, Toth K, Al-Homrani M, Husain M, Beeson G, Ball L, Helke K, Husain S, Garrett-Mayer E, Hardiman G, Mehrotra M, Nishimura MI, Beeson CC, Bupp MG, Wu J, Ogretmen B, Paulos CM, Rathmell J, Yu XZ, Mehrotra S.

Cell Metab. 2018 Jan 9;27(1):85-100.e8. doi: 10.1016/j.cmet.2017.10.006. Epub 2017 Nov 9.

18.

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells.

Bowers JS, Majchrzak K, Nelson MH, Aksoy BA, Wyatt MM, Smith AS, Bailey SR, Neal LR, Hammerbacher JE, Paulos CM.

Front Immunol. 2017 Sep 29;8:1221. doi: 10.3389/fimmu.2017.01221. eCollection 2017.

19.

Inducible Enhancement of T Cell Function and Anti-tumor Activity after Adoptive Transfer.

Wrangle J, Paulos CM, Smith TW Jr, Nishimura MI, Rubinstein MP.

Mol Ther. 2017 Sep 6;25(9):1995-1996. doi: 10.1016/j.ymthe.2017.08.002. Epub 2017 Aug 19. No abstract available.

20.

The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies.

Neal LR, Bailey SR, Wyatt MM, Bowers JS, Majchrzak K, Nelson MH, Haupt C, Paulos CM, Varela JC.

J Immunol Res Ther. 2017;2(1):68-79. Epub 2017 Jun 26.

21.

Platelets subvert T cell immunity against cancer via GARP-TGFβ axis.

Rachidi S, Metelli A, Riesenberg B, Wu BX, Nelson MH, Wallace C, Paulos CM, Rubinstein MP, Garrett-Mayer E, Hennig M, Bearden DW, Yang Y, Liu B, Li Z.

Sci Immunol. 2017 May 5;2(11). pii: eaai7911. doi: 10.1126/sciimmunol.aai7911.

22.

Resident memory T cells in the skin mediate durable immunity to melanoma.

Malik BT, Byrne KT, Vella JL, Zhang P, Shabaneh TB, Steinberg SM, Molodtsov AK, Bowers JS, Angeles CV, Paulos CM, Huang YH, Turk MJ.

Sci Immunol. 2017 Apr 14;2(10). pii: eaam6346. doi: 10.1126/sciimmunol.aam6346.

23.

Modulation of Endoplasmic Reticulum Stress Controls CD4+ T-cell Activation and Antitumor Function.

Thaxton JE, Wallace C, Riesenberg B, Zhang Y, Paulos CM, Beeson CC, Liu B, Li Z.

Cancer Immunol Res. 2017 Aug;5(8):666-675. doi: 10.1158/2326-6066.CIR-17-0081. Epub 2017 Jun 22.

24.

β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.

Majchrzak K, Nelson MH, Bowers JS, Bailey SR, Wyatt MM, Wrangle JM, Rubinstein MP, Varela JC, Li Z, Himes RA, Chan SS, Paulos CM.

JCI Insight. 2017 Apr 20;2(8). pii: 90547. doi: 10.1172/jci.insight.90547. eCollection 2017 Apr 20.

25.

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

Mehrotra S, Britten CD, Chin S, Garrett-Mayer E, Cloud CA, Li M, Scurti G, Salem ML, Nelson MH, Thomas MB, Paulos CM, Salazar AM, Nishimura MI, Rubinstein MP, Li Z, Cole DJ.

J Hematol Oncol. 2017 Apr 7;10(1):82. doi: 10.1186/s13045-017-0459-2.

26.

Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.

Bowers JS, Nelson MH, Majchrzak K, Bailey SR, Rohrer B, Kaiser AD, Atkinson C, Gattinoni L, Paulos CM.

JCI Insight. 2017 Mar 9;2(5):e90772. doi: 10.1172/jci.insight.90772.

27.

Murine Th17 cells utilize IL-2 receptor gamma chain cytokines but are resistant to cytokine withdrawal-induced apoptosis.

Neitzke DJ, Bowers JS, Andrijauskaite K, O'Connell NS, Garrett-Mayer E, Wrangle J, Li Z, Paulos CM, Cole DJ, Rubinstein MP.

Cancer Immunol Immunother. 2017 Jun;66(6):737-751. doi: 10.1007/s00262-017-1965-3. Epub 2017 Mar 9.

28.

Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity.

Hu X, Liu X, Moisan J, Wang Y, Lesch CA, Spooner C, Morgan RW, Zawidzka EM, Mertz D, Bousley D, Majchrzak K, Kryczek I, Taylor C, Van Huis C, Skalitzky D, Hurd A, Aicher TD, Toogood PL, Glick GD, Paulos CM, Zou W, Carter LL.

Oncoimmunology. 2016 Nov 4;5(12):e1254854. doi: 10.1080/2162402X.2016.1254854. eCollection 2016.

29.

Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy.

Zhu P, Bailey SR, Lei B, Paulos CM, Atkinson C, Tomlinson S.

Transplantation. 2017 Apr;101(4):e75-e85. doi: 10.1097/TP.0000000000001625.

30.

Harnessing the IL-7/IL-7Rα axis to improve tumor immunotherapy.

Johnson CB, Wrangle J, Mehrotra S, Li Z, Paulos CM, Cole DJ, Surh CD, Rubinstein MP.

Oncoimmunology. 2016 Jan 19;5(5):e1122865. doi: 10.1080/2162402X.2015.1122865. eCollection 2016 May.

31.

Lack of p53 Augments Antitumor Functions in Cytolytic T Cells.

Banerjee A, Thyagarajan K, Chatterjee S, Chakraborty P, Kesarwani P, Soloshchenko M, Al-Hommrani M, Andrijauskaite K, Moxley K, Janakiraman H, Scheffel MJ, Helke K, Armenson K, Palanisamy V, Rubinstein MP, Mayer EG, Cole DJ, Paulos CM, Christina-Voelkel-Johnson, Nishimura MI, Mehrotra S.

Cancer Res. 2016 Sep 15;76(18):5229-5240. doi: 10.1158/0008-5472.CAN-15-1798. Epub 2016 Jul 27.

32.

Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.

Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM.

J Immunother Cancer. 2016 Feb 16;4:6. doi: 10.1186/s40425-016-0110-8. eCollection 2016.

33.

Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic.

Majchrzak K, Nelson MH, Bailey SR, Bowers JS, Yu XZ, Rubinstein MP, Himes RA, Paulos CM.

Cancer Immunol Immunother. 2016 Mar;65(3):247-59. doi: 10.1007/s00262-016-1797-6. Epub 2016 Jan 29. Review.

34.

IL-2Rα mediates temporal regulation of IL-2 signaling and enhances immunotherapy.

Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP.

Sci Transl Med. 2015 Oct 28;7(311):311ra170. doi: 10.1126/scitranslmed.aac8155.

35.

IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells.

Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP.

Cancer Gene Ther. 2015 Jul;22(7):360-7. doi: 10.1038/cgt.2015.28. Epub 2015 Jul 17.

36.

Harnessing the Microbiome to Enhance Cancer Immunotherapy.

Nelson MH, Diven MA, Huff LW, Paulos CM.

J Immunol Res. 2015;2015:368736. doi: 10.1155/2015/368736. Epub 2015 May 25. Review.

37.

Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.

Bowers JS, Nelson MH, Kundimi S, Bailey SR, Huff LW, Schwartz KM, Cole DJ, Rubinstein MP, Paulos CM.

Clin Cancer Res. 2015 Jun 1;21(11):2546-57. doi: 10.1158/1078-0432.CCR-14-2294. Epub 2015 Apr 22.

38.

Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells.

Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams KM, Johnson CB, Li M, Scurti GM, Salem ML, Paulos CM, Garrett-Mayer E, Mehrotra S, Cole DJ.

Cancer Immunol Immunother. 2015 May;64(5):539-49. doi: 10.1007/s00262-015-1655-y. Epub 2015 Feb 13.

39.

Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.

Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD Jr, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH.

Cancer Immunol Res. 2015 Apr;3(4):356-67. doi: 10.1158/2326-6066.CIR-14-0186. Epub 2015 Jan 19.

40.

The inducible costimulator augments Tc17 cell responses to self and tumor tissue.

Nelson MH, Kundimi S, Bowers JS, Rogers CE, Huff LW, Schwartz KM, Thyagarajan K, Little EC, Mehrotra S, Cole DJ, Rubinstein MP, Paulos CM.

J Immunol. 2015 Feb 15;194(4):1737-47. doi: 10.4049/jimmunol.1401082. Epub 2015 Jan 9.

41.

Novel immunotherapies for hematologic malignancies.

Nelson MH, Paulos CM.

Immunol Rev. 2015 Jan;263(1):90-105. doi: 10.1111/imr.12245. Review.

42.

Reducing CD73 expression by IL1β-Programmed Th17 cells improves immunotherapeutic control of tumors.

Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, Yu XZ, Mehrotra S.

Cancer Res. 2014 Nov 1;74(21):6048-59. doi: 10.1158/0008-5472.CAN-14-1450. Epub 2014 Sep 9.

43.

Folate receptor-β in activated macrophages: ligand binding and receptor recycling kinetics.

Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos CM, Reddy J, Xu LC, Low PS.

Mol Pharm. 2014 Oct 6;11(10):3609-16. doi: 10.1021/mp500348e. Epub 2014 Sep 12.

PMID:
25166491
44.

Th17 cells in cancer: the ultimate identity crisis.

Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM.

Front Immunol. 2014 Jun 17;5:276. doi: 10.3389/fimmu.2014.00276. eCollection 2014. Review.

45.

Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host.

Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ.

J Am Coll Surg. 2012 Apr;214(4):700-7; discussion 707-8. doi: 10.1016/j.jamcollsurg.2011.12.034. Epub 2012 Feb 22.

46.

A human memory T cell subset with stem cell-like properties.

Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP.

Nat Med. 2011 Sep 18;17(10):1290-7. doi: 10.1038/nm.2446.

47.

The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells.

Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH.

Sci Transl Med. 2010 Oct 27;2(55):55ra78. doi: 10.1126/scitranslmed.3000448.

48.

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.

Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH.

Cancer Res. 2010 Nov 15;70(22):9053-61. doi: 10.1158/0008-5472.CAN-10-2880. Epub 2010 Oct 5.

49.

Putting the brakes on BTLA in T cell-mediated cancer immunotherapy.

Paulos CM, June CH.

J Clin Invest. 2010 Jan;120(1):76-80. doi: 10.1172/JCI41811. Epub 2009 Dec 28.

50.

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.

Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP.

J Immunother. 2010 Jan;33(1):1-7. doi: 10.1097/CJI.0b013e3181b88ffc.

Supplemental Content

Loading ...
Support Center